Long-term treatment with topiramate monotherapy in epilepsy

Rationale: To describe long-term outcomes of topiramate (TPM) treatment in epilepsy (TOP-GER-11). Methods: Subjects with a diagnosis of epilepsy (ILAE, 1989) who had completed one of two recent trials with topiramate (TOP-GER-5 and TOP-GER-12) were eligible for this 12-month prospective, non-interventional trial. Patients were evaluated during their previous trial and after 3, 6, 9, and 12 months during this trial (seizure frequency, adverse events [AE]). A post-hoc gender-based analysis was added. Results: Median follow up was 19 months (ITT=102 patients, 51% male, mean age 43±17). Mean duration of epilepsy in…